Search results
Results from the WOW.Com Content Network
Esketamine, sold under the brand names Spravato (for depression) and Ketanest (for anesthesia) among others, [10] [12] is the S(+) enantiomer of ketamine. [5] [13] It is a dissociative hallucinogen drug used as a general anesthetic and as an antidepressant for treatment of depression.
The more active enantiomer, esketamine (S-ketamine), is also available for medical use under the brand name Ketanest S, [136] while the less active enantiomer, arketamine (R-ketamine), has never been marketed as an enantiopure drug for clinical use. While S-ketamine is more effective as an analgesic and anesthetic through NMDA receptor ...
More evidence for esketamine use in depression treatment. ... “Ketamine is a safe medication when used under appropriate professional supervision, so FDA approval will lead to a safer, ...
The main ingredient for the spray is esketamine hydrochloride, which is the “chemical cousin” of ketamine. Ketamine has been used by clinics across the U.S. to treat depression, anxiety and ...
The US Food and Drug Administration (FDA) first approved the use of intranasal esketamine —an enantiomer of ketamine—for the use of ketamine-derived therapy for treatment-resistant depression, in 2019, [11] leading to the creation and expansion of telemedicine-based companies that practice KAP, such as Mindbloom. [12]
Esketamine is derived from a pediatric anesthetic called ketamine. Through research pioneered at Yale University, it was discovered that the drug seemed to lift heavy, recalcitrant depression ...
In 2019, esketamine, an NMDA antagonizing enantiomer of ketamine, was approved for use as an antidepressant in the United States. [17] In 2022, Auvelity was approved by the FDA for the treatment of depression. [citation needed] This combination medication contains dextromethorphan, an NMDA receptor antagonist.
Off-label use is when a doctor prescribes a drug for non-FDA-approved uses. ... Spravato is the brand name for an esketamine nasal spray that the FDA has approved for treatment-resistant depression.